Objectives This longitudinal study compared emerging plasma biomarkers for neurodegenerative
disease between controls, patients with Alzheimer’s disease (AD), Lewy body …

Plasma biomarkers for Alzheimer’s disease-related pathologies have undergone rapid
developments during the past few years, and there are now well-validated blood tests for amyloid …

Alzheimer’s disease (AD) is increasingly prevalent worldwide, and disease‐modifying
treatments may soon be at hand; hence, now, more than ever, there is a need to develop …

Background There are few validated fluid biomarkers in frontotemporal dementia (FTD). Glial
fibrillary acidic protein (GFAP) is a measure of astrogliosis, a known pathological process …

Background Biomarkers that can track disease onset and progression in autosomal dominant
Alzheimer’s disease (ADAD) are needed. We investigate whether serum neurofilament …

Background The discovery that heterozygous missense mutations in the gene encoding
triggering receptor expressed on myeloid cells 2 (TREM2) are risk factors for Alzheimer’s …

Axonal injury is a key determinant of long-term outcomes after traumatic brain injury (TBI) but
has been difficult to measure clinically. Fluid biomarker assays can now sensitively quantify …

Intronic GGGGCC repeat expansions in C9orf72 are the most common known cause of
frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ), which are …

The neurodegenerative disorder Alzheimer's disease is characterised by the formation of β-amyloid
plaques and neurofibrillary tangles in the brain parenchyma, which cause synapse …

Soluble triggering receptor expressed on myeloid cells 2 (sTREM2) in cerebrospinal fluid (CSF)
has been associated with Alzheimer’s disease (AD). TREM2 plays a critical role in …